A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)
Stopped The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.
Conditions
- Systemic Lupus Erythematosus
Interventions
- DRUG: Prednisone
- DRUG: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)
- DRUG: Methylprednisolone
- DRUG: Ocrelizumab
- DRUG: Placebo
Sponsor
Genentech, Inc.
Collaborators